Translational research of new developments in targeted therapy of colorectal cancer

• Published in: Pathology, research and practice research and practice, 2023-12, Vol.252, p.154888-154888, Article 154888
• Main Authors: Yang, Lei, Atakhanova, Nigora, Arellano, Meryelem Tania Churampi, Mohamed, Mohammed Yassen, Hani, Thamer, Fahdil, Ali A, Castillo-Acobo, Roxana Yolanda, Juyal, Ashima, Hussein, Ahlam Kadhim, Amin, Ali H, Pecho, Renzon Daniel Cosme, Akhavan-Sigari, Reza
• Format: Article
• Language: English
• Subjects: CAR-T cells; Colorectal cancer; Monoclonal antibodies; Small molecule inhibitors; Targeted therapies
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2023.154888

A severe global health concern is the rising incidence and mortality rate of colorectal cancer (CRC). Chemotherapy, which is typically used to treat CRC, is known to have limited specificity and can have noticeable side effects. A paradigm shift in cancer treatment has been brought about by the development of targeted therapies, which has led to the appearance of pharmacological agents with improved efficacy and decreased toxicity. Epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (HER2), and BRAF are among the molecular targets covered in this review that are used in targeted therapy for CRC. The current discussion also covers advancements in targeted therapeutic approaches, such as antibody-drug conjugates, immune checkpoint inhibitors, and chimeric antigen receptor (CAR) T-cell therapy. A review of the clinical trials and application of these particular therapies in treating CRC is also done. Despite the improvements in targeted therapy for CRC, problems such as drug resistance and patient selection remain to be solved. Despite this, targeted therapies have offered fresh possibilities for identifying and treating CRC, paving the way for the development of personalized medicine and extending the life expectancy and general well-being of CRC patients.